European journal of gastroenterology & hepatology
-
Eur J Gastroenterol Hepatol · Oct 1998
Randomized Controlled Trial Clinical TrialTreatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus. ⋯ The 5-hydroxytryptamine receptor type 3 antagonist ondansetron has a small, but significant positive effect on pruritus in chronic liver disease as compared to placebo.